Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.
Also called NCT03284827
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 235 participants
- Registry
-
NCT03284827
-
- Other papers using this trial's data
- Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial
- Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Hong Kong SAR China, South Korea, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT03284827. Randomized; no masking; primary purpose prevention. Start 2018-03-15 (actual); primary completion 2021-10-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
- Acronym
- ADAPT-TAVR
- Condition
- Aortic Valve Stenosis
- Intervention (Drug)
- NOAC
- Intervention (Drug)
- DAPT
- Lead sponsor
- Duk-Woo Park, MD
- Collaborator
- CardioVascular Research Foundation, Korea
- Collaborator
- Daiichi Sankyo Korea Co., Ltd.
Record details
- Record id
cardio:ct-nct03284827- Content hash
baf2ef8576a9c0e28533718c9ce8781d40df2057a45151a93a6ab1d5a4c21261